Many efforts have been made for the treatment of lung cancer, including the “hotspot” immunotherapy, which primarily relies on the immune checkpoint blockade (ICB) against programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1). This evidence concerns the gene PDCD1 and lung cancer.